Surrozen (NASDAQ:SRZN) Director Tim Kutzkey Buys 2,562 Shares of Stock

Surrozen, Inc. (NASDAQ:SRZN) Director Tim Kutzkey purchased 2,562 shares of the company’s stock in a transaction on Friday, January 16th. The shares were bought at an average price of $20.00 per share, for a total transaction of $51,240.00. Following the completion of the transaction, the director directly owned 1,007,090 shares in the company, valued at $20,141,800. This represents a 0.26% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Tim Kutzkey also recently made the following trade(s):

• On Tuesday, January 20th, Tim Kutzkey purchased 18,052 shares of Surrozen stock. The shares were purchased at an average cost of $19.60 per share, with a total value of $353,819.20.
• On Thursday, January 15th, Tim Kutzkey bought 11,893 shares of Surrozen stock. The shares were purchased at an average cost of $19.89 per share, for a total transaction of $236,551.77.
• On Wednesday, January 14th, Tim Kutzkey purchased 5,523 shares of Surrozen stock. The stock was bought at an average cost of $19.99 per share, for a total transaction of $110,404.77.
• On Tuesday, January 13th, Tim Kutzkey bought 12,470 shares of Surrozen stock. The shares were bought at an average cost of $19.80 per share, with a total value of $246,906.00.
• On Tuesday, January 6th, Tim Kutzkey bought 15,100 shares of Surrozen stock. The stock was purchased at an average price of $19.89 per share, with a total value of $300,339.00.
• On Friday, December 5th, Tim Kutzkey acquired 30,884 shares of Surrozen stock. The stock was purchased at an average cost of $19.54 per share, with a total value of $603,473.36.
• On Thursday, December 4th, Tim Kutzkey bought 5,266 shares of Surrozen stock. The shares were purchased at an average cost of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Tim Kutzkey acquired 315,457 shares of Surrozen stock. The stock was acquired at an average cost of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Stock Performance

Shares of NASDAQ SRZN traded down $2.02 during mid-day trading on Tuesday, reaching $17.98. The company had a trading volume of 62,608 shares, compared to its average volume of 59,333. The company has a market capitalization of $154.09 million, a price-to-earnings ratio of -0.80 and a beta of 0.58. The stock has a fifty day moving average of $18.98 and a two-hundred day moving average of $14.13. Surrozen, Inc. has a 12-month low of $5.90 and a 12-month high of $24.94.

Surrozen (NASDAQ:SRZN) last issued its earnings results on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). The firm had revenue of $0.98 million during the quarter. Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. Sell-side analysts forecast that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SRZN has been the topic of a number of recent analyst reports. Wall Street Zen upgraded Surrozen to a “sell” rating in a research note on Friday, November 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. Finally, Lifesci Capital raised Surrozen to a “strong-buy” rating in a research report on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Surrozen presently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Institutional Trading of Surrozen

Several large investors have recently added to or reduced their stakes in SRZN. Stempoint Capital LP increased its holdings in shares of Surrozen by 185.1% during the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock worth $6,138,000 after buying an additional 445,713 shares in the last quarter. Braidwell LP bought a new stake in Surrozen during the 2nd quarter worth approximately $1,252,000. Millennium Management LLC acquired a new stake in Surrozen during the 3rd quarter valued at $1,414,000. Schonfeld Strategic Advisors LLC bought a new position in Surrozen in the 3rd quarter valued at $889,000. Finally, Armistice Capital LLC bought a new position in Surrozen in the 2nd quarter valued at $536,000. 66.57% of the stock is owned by institutional investors.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.